Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...

Full description

Bibliographic Details
Main Authors: Rodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, Marc Humbert, John Mattson, Arno Fritsch, Michael Krowka
Format: Article
Language:English
Published: SAGE Publishing 2018-05-01
Series:Pulmonary Circulation
Online Access:https://doi.org/10.1177/2045894018769305
Description
Summary:In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
ISSN:2045-8940

Similar Items